ENSAIOS GECP -

| RESERVED AREA | LANGUAGE

Lung Cancer Study Group

CLINICAL TRIALS GECP

1. Prospective study, phase II, to evaluate the efficacy and toxicity of an induction chemotherapy regimen with paclitaxel and carboplatin and concurrent chemotherapy + radiotherapy in radically treatable patients with NSCLC, stage III.
- Presented at the 11º World Conference on Lung Cancer, 3-6 July 2005, Barcelona, Spain

2. Duration of chemotherapy in non-small cell lung carcinoma. Multicentric randomized study of four versus six cycles of carboplatin and gemcitabine
- 220 patients included
- Participation of 10 Centers (CH Coimbra, CH Vila Nova de Gaia, H Sta Maria, H Egas Moniz, CH Vila Real / Peso da Régua, HSM Braga, IPO Porto, H Pulido Valente, CH Cova da Beira, HSM Guarda)
- Presented at the 11th World Conference on Lung Cancer, 3-6 July 2005, Barcelona, Spain (preliminary results)
- Presented at 12th World Conference on Lung Cancer, 2-6 September, Seoul, Korea, 2007 (final results)

Phase II study comparing carboplatin and gemcitabine (continuous perfusion at a constant rate) with carboplatin and gemcitabine (conventional perfusion) as first-line QT for CPNPC, stages IIIB and IV
- Presented at 12th World Conference on Lung Cancer, 2-6 September, Seoul, Korea, 2007

4. Phase II, multicentre, randomized clinical study of weekly topotecan versus topotecan in a standard 5 consecutive days regímen in the treatment of recurrent small cell lung cancer

5. Open Label, uncontrolled, multicenter phase II study evaluating the efficacy and safety of Cetuximab in combination with cisplatin & gemcitabine as first line therapy in patients with advanced non small cell lung cancer (COIMBRA)
- 49 patients included
- Participation of 6 Centers (CH Coimbra, CH Vila Nova de Gaia, CH Trás os Montes and Alto Douro, H Sta. Maria, HSS, H Pulido Valente)
- Presented at the 3rd GECP Congress, 23 to 25 October 2008, Albufeira
- Presented at the 13th World Conference on Lung Cancer, July 31 - August 4, 2009. San Francisco, USA

6. Observational study to assess the Quality of Life in patients undergoing 2nd line chemotherapy for Non-Small Cell Lung Cancer (LISBON)
- 219 patients included
- Participation of 18 Centers (H. Santa Maria, CH Coimbra, H S.João, CH Vila Nova Gaia, IPO Porto, HD Faro, IDP Aveiro, HD Santarém, H ES Évora, CH Trás os Montes and Alto Douro, H Egas Moniz, H Garcia da Orta, HJF Beja, HSM Braga, CH Setúbal, IPO Lisboa, H Pulido Valente, CH Cova da Beira)
- Presented at the 14th World Conference on Lung Cancer, July 3-7 2011, Amsterdam

7. Phase II, open-label study of erlotinib in patients with locally advanced or metastatic non-small cell lung cancer who present activating mutations in the tyrosine kinase domain of epidermal growth factor receptor (MUTAR)
- 30 patients included
- Participation of 7 Centers (CH S. João, CH Vila Nova de Gaia, CH Lisbon North, CH Coimbra, IPO Lisbon, IPO Porto, CH Aveiro)
- Presented at the 6th Congress of the Lung Cancer Study Group, 9-11 October 2014, Lisbon

8. Therapeutic options for 3rd line chemotherapy in patients with non-small cell lung cancer who received erlotinib in 2nd line (ÉVORA)
- 55 patients included
- Participation of 7 Centers (CH Coimbra, IPO Lisbon, H Santa Maria, CH Vila Nova de Gaia / Espinho, H São Bernardo, H São João, CH Trás-os-Montes and Alto Douro)
- Presented at the XXIX Pulmonology Congress, 25-27 October 2013, Epic Sana, Algarve

9. Determination of the relationship between rapid progression in 2nd line of chemotherapy and response, and of the time until progression in 1st line of chemotherapy, in patients with advanced non-small cell lung cancer (GAIA)

10. Study Quality of Way of Lung Cancer patients receiving treatment with antiemetics as a support therapy for chemotherapy (SANTARÉM)
- 124 patients included
- Participation of 9 Centers (CH VN Gaia, CH Trás os Montes and Alto Douro, H Braga, H Aveiro, CH Santa Maria, CH Coimbra, CH between Douro and Vouga, IPO Lisbon, H S: João)
- Presented at the 39th ESMO Congress, 26-30 September 2014, Madrid
- Presented at the 6th Congress of the Lung Cancer Study Group, 9-11 October 2014, Lisbon

©2020-25 Copyright GECP | All Rights Reserved | Contributors | Powered by JanelaWeb